NASDAQ:EGRX - Eagle Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$42.40 +0.36 (+0.86 %)
(As of 01/23/2019 04:00 PM ET)
Previous Close$42.04
Today's Range$41.62 - $43.76
52-Week Range$36.03 - $85.66
Volume189,469 shs
Average Volume190,193 shs
Market Capitalization$632.31 million
P/E Ratio12.58
Dividend YieldN/A
Beta1.84
Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL). Its product candidates includes include EP-3101, (bendamustine ready-to-dilute) for CLL and indolent B-cell NHL; EP-4104, a dantrolene sodium for exertional heat stroke; EGL-4104-C-1702, dantrolene sodium for drug induced hyperthermia; EP-5101 (pemetrexed) for lung cancer and mesothelioma; and EGL-5385-C-1701 (fulvestrant) for breast cancer. Eagle Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Receive EGRX News and Ratings via Email

Sign-up to receive the latest news and ratings for EGRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EGRX
CUSIPN/A
Phone201-326-5300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$236.71 million
Cash Flow$3.6838 per share
Book Value$12.01 per share

Profitability

Net Income$51.94 million

Miscellaneous

Employees108
Market Cap$632.31 million
OptionableOptionable

Eagle Pharmaceuticals (NASDAQ:EGRX) Frequently Asked Questions

What is Eagle Pharmaceuticals' stock symbol?

Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX."

How will Eagle Pharmaceuticals' stock buyback program work?

Eagle Pharmaceuticals announced that its Board of Directors has initiated a stock buyback program on Thursday, August 10th 2017, which authorizes the company to buyback $100,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to buy up to 13.3% of its stock through open market purchases. Stock buyback programs are generally an indication that the company's leadership believes its stock is undervalued.

How were Eagle Pharmaceuticals' earnings last quarter?

Eagle Pharmaceuticals Inc (NASDAQ:EGRX) announced its quarterly earnings data on Thursday, November, 1st. The specialty pharmaceutical company reported $1.18 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.91 by $0.27. The specialty pharmaceutical company earned $51.34 million during the quarter, compared to analysts' expectations of $52.70 million. Eagle Pharmaceuticals had a net margin of 13.92% and a return on equity of 17.62%. The business's quarterly revenue was down 18.5% on a year-over-year basis. During the same period in the prior year, the firm earned $1.22 earnings per share. View Eagle Pharmaceuticals' Earnings History.

When is Eagle Pharmaceuticals' next earnings date?

Eagle Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, February 25th 2019. View Earnings Estimates for Eagle Pharmaceuticals.

What guidance has Eagle Pharmaceuticals issued on next quarter's earnings?

Eagle Pharmaceuticals issued an update on its third quarter earnings guidance on Tuesday, October, 30th. The company provided EPS guidance of $1.18 for the period, compared to the Thomson Reuters consensus estimate of $0.97. The company issued revenue guidance of $51 million, compared to the consensus revenue estimate of $55.23 million.

What price target have analysts set for EGRX?

4 equities research analysts have issued 12 month target prices for Eagle Pharmaceuticals' stock. Their forecasts range from $52.00 to $80.00. On average, they expect Eagle Pharmaceuticals' stock price to reach $62.50 in the next year. This suggests a possible upside of 47.4% from the stock's current price. View Analyst Price Targets for Eagle Pharmaceuticals.

What is the consensus analysts' recommendation for Eagle Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eagle Pharmaceuticals in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Eagle Pharmaceuticals.

What are Wall Street analysts saying about Eagle Pharmaceuticals stock?

Here are some recent quotes from research analysts about Eagle Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey. " (1/18/2019)
  • 2. Cantor Fitzgerald analysts commented, "Eagle has carved out a leading position in the specialty pharma market, via its 505(b) (2) strategy. We expect upwards earnings revisions to the Street’s current forecasts as the company advances its pipeline and provides date-certain launch timeframes for its pipeline. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $80." (10/3/2018)
  • 3. Mizuho analysts commented, "We don’t yet have this product in our model, and don’t expect it to be a meaningful revenue generator because Treanda powder currently has minimal market share. Big bag" may provide insurance if Eagle fails to bar Treanda generics from the market via its Orphan Drug litigation, in our view. The Fulvestrant clinical trial is fully enrolled, and data are expected in the fall. Additionally, the FDA accepted Eagle’s Vasostrict ANDA, which Endo indicated would be subject to the full litigation pathway. We have no estimates for the Ryanodex program for nerve agent exposure and note that Eagle did not provide an update on its drug- induced hyperthermia program, which we believe could get dropped. We summarize 1Q:18 performance below and reiterate our Underperform rating." (5/10/2018)

Has Eagle Pharmaceuticals been receiving favorable news coverage?

News coverage about EGRX stock has been trending very positive on Wednesday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Eagle Pharmaceuticals earned a coverage optimism score of 3.7 on InfoTrie's scale. They also gave news articles about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near future.

Who are some of Eagle Pharmaceuticals' key competitors?

Who are Eagle Pharmaceuticals' key executives?

Eagle Pharmaceuticals' management team includes the folowing people:
  • Mr. Scott L. Tarriff, CEO & Director (Age 58)
  • Mr. David M. Pernock, Pres & Chief Operating Officer (Age 65)
  • Mr. Pete A. Meyers, Chief Financial Officer (Age 48)
  • Dr. Adrian Hepner, Exec. VP & Chief Medical Officer (Age 57)
  • Mr. Daniel O'Connor, Exec. VP of Biologics and Corp. Devel. (Age 38)

Who are Eagle Pharmaceuticals' major shareholders?

Eagle Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Scout Investments Inc. (0.38%), Campbell Newman Asset Management Inc. (0.06%) and Bowling Portfolio Management LLC (0.05%). Company insiders that own Eagle Pharmaceuticals stock include David Pernock, Douglas L Braunstein, Pete A Meyers, Proquest Investments Iv, LP, Richard A Edlin, Sander A Flaum, Scott Tarriff and Steven L Krill. View Institutional Ownership Trends for Eagle Pharmaceuticals.

Which major investors are buying Eagle Pharmaceuticals stock?

EGRX stock was acquired by a variety of institutional investors in the last quarter, including Scout Investments Inc., Bowling Portfolio Management LLC and Campbell Newman Asset Management Inc.. Company insiders that have bought Eagle Pharmaceuticals stock in the last two years include David Pernock, Douglas L Braunstein, Pete A Meyers and Richard A Edlin. View Insider Buying and Selling for Eagle Pharmaceuticals.

How do I buy shares of Eagle Pharmaceuticals?

Shares of EGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eagle Pharmaceuticals' stock price today?

One share of EGRX stock can currently be purchased for approximately $42.40.

How big of a company is Eagle Pharmaceuticals?

Eagle Pharmaceuticals has a market capitalization of $632.31 million and generates $236.71 million in revenue each year. The specialty pharmaceutical company earns $51.94 million in net income (profit) each year or $3.37 on an earnings per share basis. Eagle Pharmaceuticals employs 108 workers across the globe.

What is Eagle Pharmaceuticals' official website?

The official website for Eagle Pharmaceuticals is http://www.eagleus.com.

How can I contact Eagle Pharmaceuticals?

Eagle Pharmaceuticals' mailing address is 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677. The specialty pharmaceutical company can be reached via phone at 201-326-5300 or via email at [email protected]


MarketBeat Community Rating for Eagle Pharmaceuticals (NASDAQ EGRX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  349 (Vote Outperform)
Underperform Votes:  209 (Vote Underperform)
Total Votes:  558
MarketBeat's community ratings are surveys of what our community members think about Eagle Pharmaceuticals and other stocks. Vote "Outperform" if you believe EGRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EGRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2019 by MarketBeat.com Staff

Featured Article: Bollinger Bands

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel